ABBV-525

N/A

Report date: 2024/02/01 17:47:33
NME

Base Information

Drug NameABBV-525
Drug Alias NameABBV-525ABBV-MALT1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitors
TargetsMucosa-associated lymphoid tissue lymphoma translocation protein 1
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A